Physician profile
Beverly Ewing
NPI 1417136144
$1,763.85
in general payments reported to CMS, 2019-2025
9 companies · $87.15 in 2025
The $87.15 reported for 2025 was less than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $125 · 2022: $29.89 · 2023: $513 · 2024: $1,008 · 2025: $87.15.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $906 · Travel and Lodging: $702.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $906.48 |
| Travel and Lodging | $702.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Modernatx, INC. | $1,360.50 | 2023-2024 | |
| Esperion Therapeutics, INC. | $124.99 | 2021 | |
| Genentech USA, INC. | $83.07 | 2023 | Polivy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $45.76 | 2022-2023 | Jardiance |
| Inspire Medical Systems, INC. | $38.67 | 2025 | Inspire |
| Otsuka America Pharmaceutical, INC. | $33.14 | 2022-2023 | Rexulti |
| Dexcom, INC. | $32.34 | 2025 | Dexcom G6 Transmitter |
| Lilly USA, LLC | $29.24 | 2023 | Mounjaro, Emgality, Jardiance |
| Ibsa Pharma INC. | $16.14 | 2025 | Flector, Licart, Tirosint |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Beverly Ewing listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.